Evidence map›Paper›PMID 40780194›Full record

ArticleCell2025

Vagal blockade of the brain-liver axis deters cancer-associated cachexia.

Aliesha Garrett, Naama Darzi, Ashlesha Deshmukh, Nataly Rosenfeld, Omer Goldman, Lital Adler, Elizabeta Bab-Dinitz, Oded Singer, Alireza Hassani Najafabadi, Chi Wut Wong and 24 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Article
  3. The causes of cachexia: key signals and the brain.Nature reviews. Endocrinology · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Mechanistic insights into the liver-brain axis during chronic liver disease.Nature reviews. Gastroenterology & hepatology · 2026
    Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Aliesha GarrettTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90024, USA; Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Naama DarziDepartment of Molecular Cell Biology, Weizmann Institute of Science, 7610001 Rehovot, Israel.
Ashlesha DeshmukhDepartment of Electrical and Computer Engineering, Duke University, Durham, NC 27708, USA; Department of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53706, USA.
Nataly RosenfeldDepartment of Molecular Cell Biology, Weizmann Institute of Science, 7610001 Rehovot, Israel.
Omer GoldmanDepartment of Molecular Cell Biology, Weizmann Institute of Science, 7610001 Rehovot, Israel.
Lital AdlerDepartment of Molecular Cell Biology, Weizmann Institute of Science, 7610001 Rehovot, Israel.
Elizabeta Bab-DinitzDepartment of Molecular Cell Biology, Weizmann Institute of Science, 7610001 Rehovot, Israel.
Oded SingerDepartment of Life Science Core Facilities, Weizmann Institute of Science, 7610001 Rehovot, Israel.
Alireza Hassani NajafabadiTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90024, USA.
Chi Wut WongGastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shree BoseDepartment of Internal Medicine, University of Chicago, Chicago, IL 60637, USA.
Peggy M RandonMedical Scientist Training Program, Vanderbilt University Medical School, Nashville, TN 37235, USA.
Francisco BustamanteTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90024, USA.
Rene LariosTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90024, USA.
Alexander BrandisDepartment of Life Science Core Facilities, Weizmann Institute of Science, 7610001 Rehovot, Israel.
Tevie MehlmanDepartment of Life Science Core Facilities, Weizmann Institute of Science, 7610001 Rehovot, Israel.
Brandon SmagloGastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ping ChangGastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jacqueline OlivaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Cara HaymakerDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Laukik NagawekarClinical Engineering and Applied Research, Abbot Laboratories, Sylmar, CA 91342, USA.
Sophie R WuDepartment of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
Yixuan HuangAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
Aidan ShenTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90024, USA.
Ahana VoraTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90024, USA.
Jon Floyd PadillaTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90024, USA.
Alissa PfefferTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90024, USA.
Gary SutherlandDepartment of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA.
Mark StarrDepartment of Medicine, Duke University, Durham, NC 27708, USA.
Teresa ZimmersDepartment of Cell, Developmental and Cancer Biology, School of Medicine, Oregon Health & Science University, Portland, OR 97239, USA.
Yangzhi ZhuTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90024, USA.
James MorizioDepartment of Electrical and Computer Engineering, Duke University, Durham, NC 27708, USA.
Ayelet ErezDepartment of Molecular Cell Biology, Weizmann Institute of Science, 7610001 Rehovot, Israel. Electronic address: ayelet.erez@weizmann.ac.il.
Xiling ShenTerasaki Institute for Biomedical Innovation, Los Angeles, CA 90024, USA; Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: xshen3@mdanderson.org.

Funding

Robust Control of the Stem Cell NicheR35GM122465 · NIGMS · TERASAKI INSTITUTE FOR BIOMEDICAL INNOVATION · PI Xiling Shen · 2017 to 2026
$5.6M
Developing a comprehensive model for peripheral nerve stimulation of gastrointestinal functionR01DK119795 · NIDDK · TERASAKI INSTITUTE FOR BIOMEDICAL INNOVATION · PI SHEN, XILING · 2019 to 2022
$1.8M
NIDDK NIH HHS R01 DK119795NIGMS NIH HHS R35 GM122465
6 · The paper itself

Abstract

Cancer-associated cachexia (CAC) is a multifactorial and currently incurable syndrome responsible for nearly one-third of cancer-related deaths. It contributes to therapy resistance and increases mortality among affected patients. In this study, we show that cancer-induced systemic inflammation alters vagal tone in CAC mouse models. This vagal dysregulation disrupts the brain-liver vagal axis, leading to a reprogramming of hepatic protein metabolism through the depletion of HNF4α, a key transcriptional regulator of liver function. The loss of HNF4α disrupts hepatic metabolism and promotes systemic inflammation, resulting in cachectic phenotypes. Interventions targeting the right cervical vagus nerve surgically, chemically, electrically, or through a non-invasive transcutaneous device attenuate CAC progression, alleviate its clinical manifestations, and synergize with chemotherapy to improve overall health and survival in mice.

Indexed as

BrainCachexiaLiverNeoplasmsVagus NerveAnimalsDisease Models, AnimalHumansInflammationMaleMiceMice, Inbred C57BLcancer-associated cachexiaHNF4αlivermetabolismneuromodulationvagus nerve

Identifiers

PMID40780194
PMCPMC12370180

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.